APONTIS PHARMA AG Enhances Forecast Following Agreement with Novartis

APONTIS PHARMA AG has upgraded its financial forecast for the year 2024 after finalizing a five-year distribution and marketing agreement with Novartis Pharma GmbH for two asthma medications in Germany. This new partnership is anticipated to bring about a significant positive change in the company's earnings and sales figures.

With this agreement, APONTIS PHARMA projects a sales contribution of approximately EUR 9 million and an earnings increase of up to EUR 1.5 million for the financial year 2024. The company has subsequently revised its sales forecast to EUR 50.7 million, up from the previously expected EUR 41.7 million. Moreover, the expected EBITDA has been adjusted to a positive EUR 3.3 million from the initially projected positive EBITDA of EUR 1.8 million.